tetano
Editor, Senior Moderator
Nat Commun
. 2025 Sep 26;16(1):8495.
doi: 10.1038/s41467-025-63399-x. Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic
Charles Whittaker[SUP] 1 2 3 [/SUP], Gregory Barnsley[SUP] 4 [/SUP], Daniela Olivera Mesa[SUP] 5 [/SUP], Victoria Cox[SUP] 5 [/SUP], Daniel J Laydon[SUP] 5 6 [/SUP], Chee Wah Tan[SUP] 7 8 [/SUP], Feng Zhu[SUP] 8 [/SUP], Rob Johnson[SUP] 5 9 [/SUP], Patrick Doohan[SUP] 5 9 [/SUP], Lilith K Whittles[SUP] 5 [/SUP], Gemma Nedjati-Gilani[SUP] 5 [/SUP], Peter Winskill[SUP] 5 [/SUP], Alexandra B Hogan[SUP] 5 10 [/SUP], Arminder Deol[SUP] 11 [/SUP], Christinah Mukandavire[SUP] 11 [/SUP], Katharina Hauck[SUP] 5 9 [/SUP], David Chien Boon Lye[SUP] 12 13 14 15 [/SUP], Lin-Fa Wang[SUP] 7 16 [/SUP], Oliver J Watson[SUP] 5 9 [/SUP], Azra C Ghani[SUP] 17 18 19 [/SUP]
Affiliations
COVID-19 has underscored the need for more timely access to vaccines during future pandemics. This has motivated development of broad-spectrum vaccines providing protection against entire viral families, which could be stockpiled and deployed rapidly following detection. Using mathematical modelling, we assess the utility of a broadly protective sarbecovirus vaccine during a hypothetical SARS-X outbreak, for a range of implementation strategies including ring-vaccination, spatial-targeting and mass vaccination of high-risk groups. Broadly protective sarbecovirus vaccine ring- or spatial strategies alone are insufficient to contain epidemics driven by a SARS-CoV-2-like virus, but when paired with rapid isolation and quarantine, can achieve containment of a SARS-CoV-1-like virus. Where suppression fails, broadly protective sarbecovirus vaccine utilisation still reduces the effective reproduction number and slows epidemic growth - buying valuable time for health-system response and virus-specific vaccine development. Vaccination of high-risk populations with the broadly protective sarbecovirus vaccine ahead of virus-specific vaccine availability could reduce mortality and enable shorter and less stringent non-pharmaceutical interventions to be imposed; results are sensitive to vaccine properties (e.g., efficacy), health system capabilities (e.g. rollout speed) and timeline to virus-specific vaccine availability. Our modelling suggests that broadly protective sarbecovirus vaccine delivery to those aged 60+ years could have averted 21-78 % of COVID-19 deaths during the pandemic's first year, depending on the size of the stockpile. Realising this potential impact will require investment in manufacturing, delivery capacity and equitable access ahead of future pandemics.
. 2025 Sep 26;16(1):8495.
doi: 10.1038/s41467-025-63399-x. Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic
Charles Whittaker[SUP] 1 2 3 [/SUP], Gregory Barnsley[SUP] 4 [/SUP], Daniela Olivera Mesa[SUP] 5 [/SUP], Victoria Cox[SUP] 5 [/SUP], Daniel J Laydon[SUP] 5 6 [/SUP], Chee Wah Tan[SUP] 7 8 [/SUP], Feng Zhu[SUP] 8 [/SUP], Rob Johnson[SUP] 5 9 [/SUP], Patrick Doohan[SUP] 5 9 [/SUP], Lilith K Whittles[SUP] 5 [/SUP], Gemma Nedjati-Gilani[SUP] 5 [/SUP], Peter Winskill[SUP] 5 [/SUP], Alexandra B Hogan[SUP] 5 10 [/SUP], Arminder Deol[SUP] 11 [/SUP], Christinah Mukandavire[SUP] 11 [/SUP], Katharina Hauck[SUP] 5 9 [/SUP], David Chien Boon Lye[SUP] 12 13 14 15 [/SUP], Lin-Fa Wang[SUP] 7 16 [/SUP], Oliver J Watson[SUP] 5 9 [/SUP], Azra C Ghani[SUP] 17 18 19 [/SUP]
Affiliations
- PMID: 41006237
- PMCID: PMC12475435
- DOI: 10.1038/s41467-025-63399-x
COVID-19 has underscored the need for more timely access to vaccines during future pandemics. This has motivated development of broad-spectrum vaccines providing protection against entire viral families, which could be stockpiled and deployed rapidly following detection. Using mathematical modelling, we assess the utility of a broadly protective sarbecovirus vaccine during a hypothetical SARS-X outbreak, for a range of implementation strategies including ring-vaccination, spatial-targeting and mass vaccination of high-risk groups. Broadly protective sarbecovirus vaccine ring- or spatial strategies alone are insufficient to contain epidemics driven by a SARS-CoV-2-like virus, but when paired with rapid isolation and quarantine, can achieve containment of a SARS-CoV-1-like virus. Where suppression fails, broadly protective sarbecovirus vaccine utilisation still reduces the effective reproduction number and slows epidemic growth - buying valuable time for health-system response and virus-specific vaccine development. Vaccination of high-risk populations with the broadly protective sarbecovirus vaccine ahead of virus-specific vaccine availability could reduce mortality and enable shorter and less stringent non-pharmaceutical interventions to be imposed; results are sensitive to vaccine properties (e.g., efficacy), health system capabilities (e.g. rollout speed) and timeline to virus-specific vaccine availability. Our modelling suggests that broadly protective sarbecovirus vaccine delivery to those aged 60+ years could have averted 21-78 % of COVID-19 deaths during the pandemic's first year, depending on the size of the stockpile. Realising this potential impact will require investment in manufacturing, delivery capacity and equitable access ahead of future pandemics.